Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs

Cereno Scientific AB

26/08/2026 07:19

Overview
Sweden biotech reported no Q2 net sales and a wider net loss yr/yr
Company completed SEK 60 mln directed share issue at a premium to market price
First site activated for global Phase IIb trial in pulmonary arterial hypertension

Outlook
Cereno expects topline results from CS014 Phase I PK-bridging study in Q3 2026
Company aims to initiate CS014 Phase IIb trial in Q3 2027, pending regulatory alignment
Cereno plans to advance CS585 toward IND-enabling activities for first-in-human Phase I study

Result Drivers
CLINICAL DEVELOPMENT COSTS - Co attributed widened loss to continued investment in clinical and preclinical programs including CS1, CS014 and CS585
PIPELINE ADVANCEMENT - Co said progress included activation of first site for global Phase IIb trial in PAH, completion of dosing in CS014 Phase I study, and ongoing preclinical work for CS585
FINANCIAL FLEXIBILITY - SEK 60 mln directed share issue completed at a premium to market price, strengthening co's financial position for clinical and regulatory activities

Company press release: ID:nMFN3q0MsV

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Earnings per share after dilution
 
-SEK 0.09
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cereno Scientific AB is SEK17.80, about 278.2% above its August 25 closing price of SEK4.71

Reuters Recommended Reads
Aug 25 - Sweden's Isofol Medical reports no Q2 revenue, net loss widens
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses
Aug 25 - Austar Lifesciences H1 profit drops on higher R&D spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)